碩士 / 臺北醫學大學 / 保健營養學系 / 92 / The aim of this study is to investigate the effect of n-3 polyunsaturated fatty acids on patients with MCI and mild to moderate Alzheimer’s Disease (AD). The study included dietary assessment, blood biochemical characteristics, blood fatty acid profiles, cognitive assessment (CDR, ADAS-cog, CASI and MMSE) and hemorheological status between drug naïve AD patients (n = 38) and gender-matched control subjects (n = 20). After first visiting, the AD groups were divided into fish oil group (n = 15) and placebo group (n = 15) for a randomized double-blinded placebo-controlled interventional study. Fish oil group received fish oil capsual (eicosapentaenic acid, EPA 1.08 g and docosahexaenic acid, DHA 0.72 g per day) as well as placebo group received olive oil capsual (oleic acid 1.8 g/day). The blood fatty acids profile, blood biochemical characteristics, and hemorheological measure at week 0, 12, 18 and cognitive assessment (CDR, ADAS-cog and CIBIC-Plus) were measured at week 0, 6, 12, 18 in two groups. In results, there were no statistical differences between groups (AD group vs. control group) on dietary assessment, blood biochemical characteristics and hemorheological test. Plasma and RBC linoleic acid (C18:2 n-6) and RBC total n-6 fatty acid in AD group were significant higher than control subjects (p < 0.05). The AD’s RBC oleic acid (C18:1 n-9) was significantly lower than control (p = 0.002). During the intervention, the dietary record showed no different between groups at each time intervals. The prothrombin time and INR were significant longer in the fish oil group (p < 0.05). The percentage of plasma C18:3 n-3, EPA, DHA total n-3 fatty acid and n-3/n-6 ratio in fish oil group were significant higher before intervention (p < 0.05). The RBC linolenic acid (C18:3 n-3) and n-3/n-6 ratio in fish oil group were significant higher before intervention (p < 0.05). The percentage of plasma and RBC palmitic acid (C16:0) and total saturated fatty acids (SFA) in placebo group were significant reduced before intervention (p < 0.05). In Fish oil group, RBC aggregation was significant reduced (p = 0.03) and RBC deformability was significant increased after intenvention (p = 0.04). There was no change of aggregation and deformability of RBC in placebo group. In cognitive assessments, the CIBIC-Plus was significantly improved in fish oil group (p = 0.017) than placebo group at week 18. However, CDR and ADAS-cog did not change. In our study, the CIBIC-plus score were improved than the placebo group and EPA, DHA and n-3/n-6 ratio were significant higher in fish oil group in 18 weeks. The increases EPA and DHA were inversed to increased deformability and decreased aggregation of RBC. In conclusion, higher blood n-6 fatty acids may contribute to the risk factor of AD development; the daily supplementation of 1.8 g fish oil (EPA 1.08 g and DHA 0.72 g) showed significant improvement in patients with MCI and mild to moderate AD. Thus, fish oil supplement could be considered as an alternative choice to prevent or improve MCI and mild to moderate AD.
| Identifer | oai:union.ndltd.org:TW/092TMC00217007 |
| Date | January 2004 |
| Creators | Yu-Wen Huang, 黃毓文 |
| Contributors | Shih-Yi Huang, 黃士懿 |
| Source Sets | National Digital Library of Theses and Dissertations in Taiwan |
| Language | zh-TW |
| Detected Language | English |
| Type | 學位論文 ; thesis |
| Format | 110 |
Page generated in 0.0211 seconds